Curaleaf (OTCMKTS:CURLF) Downgraded by Zacks Research to “Hold”

Curaleaf (OTCMKTS:CURLF) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Curaleaf Stock Performance

OTCMKTS:CURLF opened at $3.64 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.56 and a quick ratio of 0.74. The firm has a 50-day moving average of $3.08 and a two-hundred day moving average of $2.71. The stock has a market cap of $2.54 billion, a P/E ratio of -28.00 and a beta of 1.53. Curaleaf has a 1-year low of $0.72 and a 1-year high of $5.05.

Curaleaf (OTCMKTS:CURLF) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.51. The company had revenue of $324.23 million during the quarter, compared to analysts’ expectations of $316.62 million. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. On average, research analysts expect that Curaleaf will post -0.1 earnings per share for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.